Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.

Cancer Sci · 2026 · PMC12861108 · PMID 41316804

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, aumolertinib plus chemotherapy showed a trend toward longer PFS from a long‐term perspective. 3.6 CNS Efficacy We performed a competing‐risk analysis estimating the risk of CNS progression at data cutoff while considering competing risks from non‐CNS progression or death.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.